Evogene (NASDAQ: EVGN) reported Q1 EPS of ($0.21), $0.02 worse than the analyst estimate of ($0.19). Revenue for the quarter came in at $312 thousand versus the consensus estimate of $230.67 thousand.

For earnings history and earnings-related data on Evogene (EVGN) click here.